The 17th China Growth-Oriented Pharmaceutical Enterprise Development Conference was officially held in Xiamen on November 22nd. During the conference, the "2023 Excellent Brand List" was grandly released. Benefit Pharmaceutical's premium flagship product "Chu Sanqing · Tetrastigma hemsleyanum Powder" made it to the list by virtue of its excellent quality. Ye Lixia, General Manager of the Formula Granule Marketing Division, took the stage to receive the award.

Chu Sanqing Tetrastigma hemsleyanum Powder selects authentic Tetrastigma hemsleyanum, a local medicinal material in Zhejiang. The entire industry chain of Tetrastigma hemsleyanum, covering R&D and breeding, GAP planting bases, GMP production, and product sales, truly realizes quality control from the source. Moreover, the application of high-speed airflow wall-breaking crushing technology significantly improves the wall-breaking rate, enabling faster efficacy.

The inclusion of "Chu Sanqing · Tetrastigma hemsleyanum Powder" in the list is a recognition of the enterprise's brand and quality. It not only represents the affirmation and recognition of Benefit's product quality by professional institutions but also serves as a strong demonstration of the continuous enhancement of Benefit's enterprise strength and brand influence. In the next step, the company will focus on promoting the inheritance and innovative development of traditional Chinese medicine, continuously expand the layout of the entire Tetrastigma hemsleyanum industry chain and the strategic layout of the traditional Chinese medicine health industry, continuously increase R&D investment, and meticulously cultivate product quality. Remaining true to its original aspiration, keeping its mission in mind, forging ahead with determination, and moving forward with steadfastness, the company will bring more high-quality products to the public eye, contributing to the high-quality development of the cause and industry of traditional Chinese medicine.